At a glance
ClinicalIndex Comparison Record- ✓Histological diagnosis of epithelial ovarian carcinoma, fallopian tube cancer, primary peritoneal carcinoma, or papillary serous mullerian carcinoma
- ✓Stage IC or greater
- ✓Previous attempted surgical debulking
- ✓Age 18 years or older
- ✕Prior chemotherapy or radiotherapy
- ✕Prior treatment with an anti-angiogenic agent
- ✕Inadequate surgical cytoreduction that could materially improve prognosis; no interval cytoreductive surgery permitted on study
- ✕Evidence of tumor involving major blood vessels on CT scan
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Evaluation of Carboplatin, Paclitaxel and Bevacizumab as First Line Chemotherapy and Consolidation for Advanced Ovarian Cancer
In Brief
A Phase 2 clinical trial evaluating Paclitaxel, Carboplatin, and 1 other intervention for Ovarian Cancer. Completed, enrolled 62 participants.
Detailed Summary
Study Design: This ia a Phase II study. Subjects: Patients with chemotherapy naive epithelial ovarian cancer; or fallopian, primary peritoneal and papillary serous mullerian tumors will be recruited. Carboplatin and Taxol (paclitaxel) will be administered concurrently with bevacizumab after surgery for 6-8 cycles every 21 (q21) days. Bevacizumab will be omitted in the first cycle, immediately post-operatively. This will be followed by one year of bevacizumab q21. Outcomes: Outcomes include toxicity, response rate, and progression free survival.
Study Details
Timeline
Interventions
Given intravenously
Given intravenously
Given intravenously